Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor
Top Cited Papers
Open Access
- 1 August 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (3) , 295-299
- https://doi.org/10.1086/421494
Abstract
Infliximab, a tumor necrosis factor (TNF) antagonist, is associated with tuberculosis (TB), but it is unknown whether this phenomenon is true of allKeywords
This publication has 12 references indexed in Scilit:
- Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance reportArthritis & Rheumatism, 2003
- Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementThe Lancet Infectious Diseases, 2003
- Risk Factors Associated with Tuberculin Skin Test Positivity among University Students and the Use of Such Factors in the Development of a Targeted Screening ProgramClinical Infectious Diseases, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Old and New Drugs Used in Rheumatoid Arthritis: A Historical PerspectiveClinical Journal of Sport Medicine, 2001
- Correction of Defective Host Response to Mycobacterium Bovis BCG Infection in TNF-Deficient Mice by Bone Marrow TransplantationLaboratory Investigation, 2000
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Postmarketing Surveillance and Adverse Drug ReactionsPublished by American Medical Association (AMA) ,1999
- The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infectionCell, 1989
- Hepatic synthesis of bile acids. Biochemical steps and mechanisms of rate controlArchives of internal medicine (1960), 1972